Scholtz & Company’s iShares Biotechnology ETF IBB Stock Holding History

Scholtz & Company’s Portfolio IBB Stock Details IBB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q1	–	Sell	-4,745	Closed	-$623K	–	43
2022 Q4	$623K	Sell	4,745 -885	-16%	-$114K	0.44%	36
2022 Q3	$756K	Buy	+5,630	New	+$699K	0.54%	34

Other funds holding IBB

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Citigroup New York $235B AUM 32.99% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Royal Bank of Canada Toronto, Ontario, Canada $570B AUM 27.57% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

BNP Paribas Financial Markets Paris, France $206B AUM 31.61% 1-Year Est. Return

Healthcare of Ontario Pension Plan (HOOPP) Trust Fund Toronto, Ontario, Canada $62.2B AUM 31.35% 1-Year Est. Return

Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return

Scholtz & Company's IBB Position: Q1 2023 in Review

Scholtz & Company sold out of iShares Biotechnology ETF (IBB) in Q1 2023, closing a stake of 4,745 shares — an estimated $623K sold.

Scholtz & Company first reported a position in IBB in Q3 2022 and held it in 2 quarters. The position peaked at $756K in Q3 2022. 866 funds tracked by Wall St. Rank hold IBB as of Q1 2023.

Scholtz & Company reported no remaining iShares Biotechnology ETF position as of Q1 2023 after selling out during the quarter.
Scholtz & Company sold 4,745 iShares Biotechnology ETF shares in Q1 2023, an estimated $623K.
Scholtz & Company first reported a position in iShares Biotechnology ETF in Q3 2022 and held it in 2 quarters.
Scholtz & Company's iShares Biotechnology ETF position peaked at $756K in Q3 2022.
866 funds tracked by Wall St. Rank held iShares Biotechnology ETF as of Q1 2023.

Based on Scholtz & Company's 13F filing for Q1 2023, filed 15 May 2023.